GLP3 (sometimes written GLP-3) is an informal name for retatrutide — Eli Lilly's investigational triple receptor agonist (LY3437943). It simultaneously activates GLP-1, GIP, and glucagon receptors, producing weight loss roughly 50-70% greater than current single GLP-1 agonists like semaglutide.

Is GLP-3 a real medication class?

GLP-3 is not an officially recognized peptide hormone or regulatory drug class the way GLP-1 is. The 'GLP-3' nickname positions retatrutide as the next-generation iteration beyond GLP-1 (semaglutide) and dual GLP-1/GIP agonists (tirzepatide). It is patient/research community shorthand, not biochemical classification.

Is GLP3-R the same as retatrutide?

Yes. GLP3-R (sometimes seen on research-peptide vendor sites) refers to the same molecule as retatrutide / LY3437943. The 'R' suffix is marketing shorthand, not a regulatory or biochemical distinction. There is one molecule with multiple informal names.

What makes the GLP-3 class different from GLP-1?

GLP-1 agonists (semaglutide, liraglutide) suppress appetite and slow gastric emptying. The GLP-3 class adds two more mechanisms: GIP activation improves insulin sensitivity and stimulates adipose tissue browning, and glucagon receptor activation raises basal metabolic rate and accelerates liver fat oxidation. Together, the three mechanisms drive larger weight loss with broader metabolic benefits.

What Is GLP3? The Triple Agonist Weight Loss Class Explained

What Is ‘GLP3 Weight Loss’ and How Is It Different?

GLP3 Weight Loss is an independent educational resource and research-product catalog focused on GLP-1 and dual/triple-agonist (GLP-3/retatrutide) science. We are not a clinic, pharmacy, or telehealth service, and we do not provide medical care, prescribe, or dispense medication. Our role is to explain the science clearly and, if you choose, connect you with independent, third-party licensed providers who handle any evaluation and treatment.

What We Provide

We publish plain-English, citation-backed education on how these medications work and what clinical trials reported, and we offer a catalog of research-use-only compounds through our Telos line. Any medical evaluation, prescribing, dosing, monitoring, and side-effect management is performed solely by the independent licensed provider you choose — not by GLP3 Weight Loss. Nothing here is medical advice.

How This Resource Is Different

We are an educational resource, not a service that treats you. Many websites in this space write prescriptions and ship medication. We do none of that. We explain the science of GLP-1 and dual/triple-agonist (GLP-3/retatrutide) medications in plain English, with citations, and — if you choose — connect you with independent, third-party licensed providers. Any prescribing, dosing, monitoring, and side-effect management is handled solely by the provider you choose.

What independent providers may offer: The independent licensed providers we can refer you to are responsible for medical evaluation, eligibility screening, contraindication review, dose decisions, and ongoing monitoring. We do not employ them, supervise their care, or take part in any treatment relationship. Whether GLP-1 or dual-agonist therapy is appropriate for you is a decision between you and that provider.

Why the Science Specialization Matters

Understanding these medications requires familiarity with dose escalation, side-effect patterns, drug interactions, patient-selection and contraindication concepts, and the long-term outcomes reported in trials involving thousands of participants. Our educational content focuses on explaining these topics neutrally so you can have an informed conversation with a licensed provider — it is not personalized advice.

An Honest View of Results

Weight-loss outcomes reported in clinical trials vary widely by individual and depend on the medication, dose, adherence, and lifestyle factors. Trial figures (such as those reported in the STEP and SURMOUNT programs) describe what was observed in studies — they are not results we offer or promise. Side effects are common, and any decision to start, change, or stop a medication should be made with your own licensed provider.

Research-Use-Only Telos Compounds

Separately from our educational content, GLP3 Weight Loss offers a catalog of research-use-only (RUO) compounds through our Telos line. These are sold strictly for laboratory and in-vitro research — not for human or veterinary use, consumption, or therapeutic purposes. Retatrutide and other investigational compounds are not approved by the U.S. FDA.

Whether you’re exploring the science for the first time or have read about other approaches, this resource is here to inform. Explore our medication guides to learn how each works, review our FAQ section for common questions, or Find a Licensed Provider to discuss whether GLP-1 or dual-agonist therapy is right for your situation.

Disclaimer: GLP3 Weight Loss is an independent educational resource and research-product catalog — not a clinic, pharmacy, or telehealth provider. We do not diagnose, treat, prescribe, or dispense, and no provider-patient relationship is created by using this site. Eligibility is determined solely by an independent licensed provider. Results reported in trials vary by individual. This is education, not medical advice; always consult your own licensed provider.